Recombinant Human Cyclin-Dependent Kinase 8, GST-tagged

• Cat.No.: CDK8-1003H
• Product Overview: Recombinant full-length human CDK8 was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.

Specification

• Cat. No.: CDK8-1003H
• Description: CDK8 is a member of the CDK family which are important regulators of cell cycle progression. CDK8 associates with Cyclin C and is a component of the RNA polymerase II holoenzyme complex that phosphorylates the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II. CDK8 regulate transcription by targeting the CDK7/cyclin H subunits of the general transcription initiation factor IIH (TFIIH). Inhibition of CDK8 expression inhibits proliferation in colon cancer cells characterized by high levels of CDK8 and beta-catenin hyperactivity. CDK8 kinase activity is necessary for β-catenin-driven transformation and for expression of several β-catenin transcriptional targets.
• Applications: Kinase Assay; Western Blot
• Molecular Weight: 84 kDa
• Expression System: Sf9 insect cells using baculovirus
• Species: Human
• Form: Recombinant protein stored in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.25 mM DTT, 0.1 mM EDTA, 0.1 mM PMSF, 25 % glycerol.
• Purity: > 80 %
• Concentration: 0.2 ug/ul
• Sequences: Full-length
• Storage: Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
• Pathways: Diabetes pathways; Gene Expression; Generic Transcription Pathway; Transcriptional Regulation of White Adipocyte Differentiation

Gene Information

• Gene Name: CDK8 cyclin-dependent kinase 8 [ Homo sapiens ]
• Official Symbol: CDK8
• Synonyms: CDK8; cyclin-dependent kinase 8; K35; MGC126074; MGC126075; OTTHUMP00000018158; protein kinase K35; CDK8 protein kinase; mediator complex subunit CDK8; cell division protein kinase 8; mediator of RNA polymerase II transcription subunit CDK8; Cyclin-dependent kinase 8; EC 2.7.11.22; EC 2.7.11.23; Cell division protein kinase 8; Mediator complex subunit CDK8; Mediator of RNA polymerase II transcription subunit CDK8; Protein kinase K35
• Gene ID: 1024
• mRNA Refseq: NM_001260
• Protein Refseq: NP_001251
• MIM: 603184
• UniProt ID: P49336
• Chromosome Location: 13q12
• Function: ATP binding; RNA polymerase II carboxy-terminal domain kinase activity; cyclin-dependent protein kinase activity; nucleotide binding; protein binding; protein kinase activity

Reviews

03/05/2020

The CDK8 protein stands as a remarkable solution that exemplifies exceptional quality and meets all my experimental requirements.

08/03/2019

I am confident that the CDK8 protein will unlock vital insights into cellular processes, propelling my scientific investigations to new heights.

10/01/2017

Its impressive purity and functional characteristics make it an ideal choice for my research endeavors, ensuring reliable and impactful results.

Q&As

Is CDK8 exclusively associated with cancer, or does it have physiological roles in normal cellular functions?

CDK8 plays essential roles in normal cellular functions, including development and tissue homeostasis. Its dysregulation, however, is implicated in cancer.

Can CDK8 inhibitors be used in combination with other cancer treatments, and if so, what are the potential benefits?

Combination therapies involving CDK8 inhibitors are being explored to enhance treatment outcomes and reduce the likelihood of resistance, providing a more comprehensive approach to cancer management.

How does CDK8 inhibition affect the cell cycle, and why is this significant in cancer therapy?

CDK8 inhibition can disrupt the cell cycle, slowing down or halting the uncontrolled cell division characteristic of cancer cells, making it a potential therapeutic strategy.

How does CDK8 influence the immune response in the tumor microenvironment?

CDK8 can modulate the expression of genes involved in immune response. Understanding its role in the tumor microenvironment may lead to novel immunotherapeutic strategies.

Are there ongoing clinical trials investigating the efficacy of CDK8 inhibitors in cancer patients?

Yes, several clinical trials are underway to assess the safety and effectiveness of CDK8 inhibitors as a targeted therapy for different types of cancer.